发明名称 |
Dosage and administration for preventing cardiotoxicity in treatment with ErbB2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents |
摘要 |
<p>Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.</p> |
申请公布号 |
AU2011338487(A1) |
申请公布日期 |
2013.07.18 |
申请号 |
AU20110338487 |
申请日期 |
2011.12.06 |
申请人 |
MERRIMACK PHARMACEUTICALS, INC. |
发明人 |
REYNOLDS, JOSEPH G.;OLIVIER, KENNETH J.;HENDRIKS, BART S.;WICKHAM, THOMAS;KLINZ, STEPHAN;GERETTI, ELENA |
分类号 |
A61K9/127;A61K31/7042;A61P35/00 |
主分类号 |
A61K9/127 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|